All In Biotech

NDA 215039 · Novartis

Vijoice

Alpelisib · Oral

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Apr 5, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

109

10 Phase 3, 22 recruiting

FAERS reports

1,873

1,427 serious, 236 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 27, 2026.

VIJOICE is indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). VIJOICE is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )

Mechanism: Alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. Gain-of-function mutations in the gene encoding the catalytic α-subunit of PI3K (PIK3CA) lead to activation of PI3Kα and Akt-signaling, cellular transformation and the generation of tumors in in vitro and in vivo models. Activating mutations in PIK3CA have been found to induce a spectrum of overgrowths and malformations comprising a wide group of clinically recognizable disorders commonly known as PROS. In an inducible mouse model of Congenital Lipomatous Overgrowth,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 24, 2024 Supplement 2 · Efficacy OrphanLetter
  • Apr 5, 2022 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelBreakthrough therapyAccelerated approvalOrphanLetterLabelReview
3 products under this application
  • VIJOICE · ALPELISIB 200MG · TABLET, ORAL · Prescription
  • VIJOICE · ALPELISIB 50MG · TABLET, ORAL · Prescription
  • VIJOICE · ALPELISIB 125MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alpelisib" as an intervention, any sponsor and status, largest first.

All 109 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hyperglycaemia351
  • malignant neoplasm progression249
  • rash210
  • diarrhoea205
  • fatigue127
  • drug ineffective124
  • nausea123
  • breast cancer metastatic117
  • death117
  • metastases to bone94
  • blood glucose increased92
  • weight decreased91

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20175
20183
201990
2020172
2021269
2022402
2023334
2024228
2025192
2026177

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vijoice (Alpelisib)

2024 spending

$8.5M

Beneficiaries

42

214 claims

Per beneficiary

$203,257

$979.44 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,894,697
2023$5,958,633
2024$8,536,782

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.